Neoimmunetech announces receipt of ind clearance to conduct window-of-opportunity trial of nt-i7 (efineptakin alfa) in patients with locally recurrent squamous cell carcinoma of head and neck

Neoimmunetech announces ind clearance for window-of-opportunity study of nt-i7 in locally recurrent squamous cell carcinoma of the head and neck.

FLUX Ratings Summary

FLUX Quant Ranking